Browse the evidence

Women diagnosed with breast cancer can safely consume soyfoods without increasing the risk of recurrence or mortality, and post-diagnosis soy intake may be associated with a decreased risk of recurrence.

If you have had breast cancer, you can eat soyfoods. They are safe and do not increase your risk of the cancer coming back. Some studies even suggest they might help, but you shouldn't start eating them just to treat the cancer—just include them as part of a healthy diet.

In patients newly diagnosed with type 2 diabetes, recent weight gain (within one year prior to diagnosis) predicts subsequent weight loss after diagnosis, whereas long-term historical weight history (weight at age 20 or changes 10 years prior) does not predict post-diagnosis weight changes.

If you have recently gained weight leading up to a type 2 diabetes diagnosis, you are statistically likely to lose weight after diagnosis compared to those who were stable or losing weight. However, your weight at age 20 or your weight trends from 10 years ago do not predict your post-diagnosis weight. Focus on your current trajectory and recent changes rather than your distant history.

Acarbose and metformin provide similar HbA1c reduction and modest weight loss in newly diagnosed Chinese type 2 diabetic patients regardless of BMI status.

For newly diagnosed Chinese type 2 diabetics, both acarbose (300mg/day) and metformin (1500mg/day) are effective first-line treatments for lowering HbA1c and achieving modest weight loss, regardless of whether you are normal weight, overweight, or obese. Acarbose may offer slightly better weight loss in overweight individuals, while metformin may be better for fasting blood glucose. The choice depends on individual tolerance and dietary habits, particularly carbohydrate intake.

In overweight patients, metformin is superior to acarbose for lowering fasting blood glucose, while acarbose is superior to metformin for lowering 2-hour post-challenge blood glucose.

If you are overweight and newly diagnosed with type 2 diabetes, metformin may be better for controlling your fasting blood sugar, while acarbose may be better for controlling your blood sugar after meals. This allows for personalized treatment based on your specific glucose profile.

Metformin is superior to acarbose for improving insulin resistance in normal weight patients, while both drugs are similar in overweight and obese patients.

If you are normal weight and newly diagnosed with type 2 diabetes, metformin may be a better choice than acarbose for improving your body's sensitivity to insulin.

GLP-1 receptor agonists provide significant cardiovascular benefits, including reduced risk of major adverse cardiovascular events (MACE) and stroke, in addition to weight loss and glycemic control.

GLP-1 agonists (like Ozempic or Victoza) do more than lower blood sugar and help with weight loss. They have been proven to reduce the risk of heart attacks, strokes, and cardiovascular death in people with Type 2 Diabetes. If you have heart disease or risk factors, these drugs may offer significant protection beyond just sugar control.

Intensive blood pressure lowering to <130 mm Hg may be better tolerated and beneficial for perimenopausal women with diabetes compared to older populations, though standard guidelines recommend <140/90 mm Hg.

Discuss with your doctor if a lower blood pressure target (below 130 systolic) is appropriate for you, as younger women may tolerate it better than older patients, potentially offering more stroke protection.

Omitting initial glucose-lowering drug treatment (GLDT) in newly diagnosed type 2 diabetes is associated with a higher 5-year risk of major adverse cardiovascular events (MACE), primarily mediated by lower initiation of statins and renin-angiotensin system inhibitors (RASi), even in patients achieving glycemic remission.

If you have newly diagnosed type 2 diabetes, even if you manage to normalize your blood sugar through diet and exercise (remission), you may still be at higher risk for heart attacks or strokes if you avoid glucose-lowering drugs. This is likely because avoiding these drugs also means you are less likely to be prescribed essential heart-protective medications like statins or blood pressure drugs. Ensure your doctor prescribes appropriate cardiovascular prevention strategies regardless of your glycemic status.

Metabolic health status (MHO vs. MUO) is a better predictor of long-term cardiovascular risk and mortality than BMI alone, with metabolically unhealthy obesity (MUO) requiring prompt intervention.

If you have obesity, ask your doctor to check your metabolic health (blood pressure, lipids, blood sugar), not just your weight. Your risk of heart disease depends more on these numbers and where you store fat (belly vs. hips) than your BMI alone. If you are metabolically unhealthy, you need prompt intervention.

Lowering blood glucose levels reverses glucose toxicity, thereby restoring beta-cell insulin secretion and enabling complete or partial remission of type 2 diabetes.

If you have Type 2 Diabetes, high blood sugar actively suppresses your pancreas's ability to make insulin. This suppression is often reversible. By aggressively lowering your blood glucose levels—through medication, intensive insulin therapy, or dietary changes—you can remove this 'glucose toxicity.' This allows your remaining beta-cells to recover function, potentially leading to remission where you no longer need medication. This is most likely if you have not had diabetes for many years and still have some beta-cell mass left.

In type 2 diabetes patients initiating insulin therapy, pre-insulin weight loss combined with rising or persistently high HbA1c is the strongest predictor of excessive post-initiation weight gain (≥5 kg).

If you are starting insulin and have lost weight recently while your blood sugar numbers were going up, expect to regain that weight. This is likely 'catch-up' weight as your body stops losing sugar through urine. It is a sign the insulin is working to correct your metabolism, not necessarily a failure of your diet. Monitor your weight, but do not let fear of this specific type of gain prevent you from starting life-saving therapy.

Metformin therapy reduces the risk of developing type 2 diabetes in patients with prediabetes, with the greatest preventive effect observed in individuals with higher baseline glycated hemoglobin (HbA1c) and a history of gestational diabetes.

If you have prediabetes, especially if your HbA1c is on the higher side (6.0-6.4%) or you had gestational diabetes, metformin is a proven, safe option to prevent type 2 diabetes. It works by improving how your liver handles glucose and insulin. It does not cause low blood sugar, making it a low-risk preventive tool when lifestyle changes alone are not enough.

Acarbose, an alpha-glucosidase inhibitor, reduces the risk of developing type 2 diabetes in patients with impaired glucose tolerance, but its effectiveness is lower than that of lifestyle modification and metformin.

Acarbose can help prevent diabetes in people with prediabetes by slowing down carb absorption, but it is less effective than lifestyle changes or metformin. It often causes bloating and stomach discomfort, leading many people to stop taking it. It is generally not the first choice for prevention.

High-dose 2'-FL supplementation (5g/day) in older adults significantly increases serum levels of Fibroblast Growth Factor 21 (FGF21) and HDL cholesterol, while depleting octanoylcarnitine.

Older adults taking 5g of 2'-FL daily may see improvements in HDL cholesterol and levels of the hormone FGF21, which regulates lipid metabolism. These changes are associated with the bloom of Bifidobacterium in the gut. The intervention is well-tolerated.

Low serum creatinine levels in early pregnancy (10-14 weeks) are associated with a significantly higher incidence of postpartum abnormal glucose metabolism (AGM) in women with a history of gestational diabetes mellitus (GDM).

If you have a history of gestational diabetes, your early pregnancy creatinine level may predict your risk of developing persistent blood sugar issues after birth. Since creatinine reflects muscle mass, and muscle is key for processing glucose, maintaining or building muscle mass through resistance training and adequate protein intake before and during pregnancy may help mitigate this risk. Discuss your creatinine levels with your endocrinologist or obstetrician as part of your GDM management plan.

In individuals with type 2 diabetes who do not carry the haptoglobin (Hp) 2-2 phenotype, maintaining an HbA1c level below 6.5% is associated with a significantly lower risk of coronary artery disease compared to maintaining levels between 7.0% and 7.9%.

If you have type 2 diabetes and do not have the haptoglobin 2-2 genetic variant, aiming for an HbA1c below 6.5% may offer better protection against heart disease than aiming for 7.0-7.9%. This suggests that personalized glycemic targets based on genetic factors could optimize cardiovascular health.

Integrase Strand Transfer Inhibitors (INSTIs), specifically Dolutegravir (DTG) and Bictegravir (BIC), are associated with significant weight gain compared to older antiretrovirals like Efavirenz (EFV) or Protease Inhibitors.

If you are starting HIV treatment, ask your doctor about INSTIs (like Dolutegravir). They are effective but may cause weight gain, especially in women and Black individuals. If weight gain is a major concern, discuss alternatives like TDF-based regimens or older agents like Efavirenz, though these may have other side effects.

The fixed-dose extended-release combination of naltrexone and bupropion (NB-ER) is the most promising pharmacotherapy for facilitating smoking cessation while preventing post-cessation weight gain in individuals with obesity.

If you smoke and have obesity, your fear of gaining weight after quitting is valid and common. Standard cessation drugs often fail to stop this weight gain. Ask your doctor about NB-ER (naltrexone/bupropion extended-release), which targets the brain pathways for both addiction and hunger, offering the best chance to quit smoking without the associated weight gain.

Obesity increases cardiovascular risk and mortality primarily through visceral adiposity and ectopic fat deposition (pericardial/epicardial), which drive endothelial dysfunction, chronic inflammation, and atherosclerosis, independent of or additive to traditional risk factors like BMI, blood pressure, and cholesterol.

Focus on reducing visceral and ectopic fat, not just total weight. Measures like waist circumference are more predictive of heart disease risk than BMI. Lifestyle interventions, particularly aerobic exercise, can reduce visceral adipose tissue even without significant weight loss, thereby lowering cardiovascular risk.

Ethnicity-specific BMI cut-offs are required for accurate diagnosis and management of obesity-related risks, particularly for South Asian populations.

If you are of South Asian descent, be aware that your risk for Type 2 Diabetes increases at a lower BMI (around 23.9 kg/m2) compared to the standard 30 kg/m2. Discuss ethnicity-specific risk assessments with your healthcare provider.

High glycemic index (GI) diets increase cardiovascular disease (CVD) risk and all-cause mortality, potentially mediated by postprandial hypotension (PPH) and oxidative stress.

Focus on the quality of carbohydrates rather than just cutting them out. Choose low-glycemic index foods like whole grains, legumes, and vegetables to avoid post-meal blood pressure drops and oxidative stress, which are linked to higher heart disease risk.

Acarbose, an alpha-glucosidase inhibitor, reduces the risk of cardiovascular disease and postprandial hypotension by slowing carbohydrate digestion and absorption.

For high-risk patients with impaired glucose tolerance, Acarbose (50-100mg at breakfast) can significantly reduce cardiovascular risk and postprandial hypotension by slowing carbohydrate absorption.

Targeted pharmacotherapy for obesity should focus on the MC4R pathway (e.g., MC4R agonists) for patients with specific genetic defects in upstream genes like POMC, PCSK1, or LEPR.

If you have a known genetic defect affecting your hunger hormones (like POMC or MC4R deficiencies), standard diets may fail. You should ask your doctor about genetic testing. If positive, you may be eligible for targeted medications like setmelanotide (Imcivree) that specifically fix the broken pathway.

A higher proportion of slow-twitch (ST) muscle fibers is associated with greater insulin sensitivity and accelerated glucose uptake, whereas a shift toward fast-twitch (FT) fibers is linked to insulin resistance.

If you are concerned about insulin resistance or metabolic health, prioritize endurance exercise. This type of training can shift your muscle phenotype toward a more insulin-sensitive state by increasing the abundance of slow-twitch fiber characteristics and oxidative enzymes. You do not need to be an elite athlete to benefit; the plasticity exists in healthy humans.